2021, Number 4
Sanitary Registration of Heberprot-P®, an innovative biotechnological medicine for the treatment of diabetic foot ulcers
Full text
Language: Spanish
References: 27
Page: 1-19
PDF size: 350.27 Kb.
ABSTRACT
Introduction: Heberprot-P® obtained its first Sanitary Registration in Cuba in 2006, and it is currently approved in 26 other countries.Objective: Describe the sanitary registration process in Mexico of the biotechnological drug Heberprot-P® for the treatment of diabetic foot ulcers.
Methods: The sanitary registration process of Heberprot-P® followed the guidelines of the sanitary regulations of Mexico on the basis of the General Health Law and the Regulation of Supplies for Health. The Pharmacopoeia of the United Mexican States and the official Mexican standards were also revised in order to comply with the requirements for the marketing of medicines in this territory.
Results: The registration process began in June 2017 in Mexico with actions to complete the documents and information required in the sanitary registration file to be submitted. Among them are the considerations of the Sub-committee on the Evaluation of Biotechnological Products and the Committee on New Molecules, the evaluation of the file by an Authorized Third Party and documents issued by the National Center for Pharmacovigilance and the Mexican Institute of Industrial Property. The application for sanitary registration was submitted to Cofepris and this was approved in May 2018.
Conclusions: The work with groups of experts allowed the Mexican authority to do a more expeditious work based on the evidence of the evaluations carried out that are part of the information of the sanitary registry. As a result of this process, Heberprot-P® was granted the Sanitary Registry in May 2018 and COFEPRIS recognized it as an innovative biotechnological medicine.
REFERENCES
Yera-Alos I, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira-Martínez M, Marrero-Rodriguez I, et al. Active Post-Marketing Surveillance of the Intralesional Administration of Human Recombinant Epidermal Growth Factor in Diabetic Foot Ulcers. BMC Pharmacol Toxicol. 2013 [acceso 15/03/2021];14(1):44. Disponible en: http://www.biomedcentral.com/2050-6511/14/44
López-Saura P, Yera-Alos I, Valenzuela-Silva C, González-Díaz O, del Río-Martín A, Berlanga- Acosta J, et al. Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers. Adv Pharmacoepidemiol Drug Safety. 2013;2:128. DOI: http://dx.doi.org/10.4172/2167-1052.1000128
Verdaguer Pérez L, Muguercia Silva J, Ayala Lafargue D, Bertrán Bahades J, Estrada Ladoy L. Experiences in the treatment with Heberprot-P(r) in patients with diabetic foot. MEDISAN. 2017 [acceso 11/07/2021];21(8):993-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192017000800005&lng=es
Alfonso SA, Rodríguez Valdés-Fauly C, Verde AL. Heberprot-p in the treatment of the ischemic diabetic foot with high risk of amputation. Invest Médicoquir. 2019 [acceso 11/07/2021];1(2). Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDREVISTA=297&IDARTICULO=88404&IDPUBLICACION=8442
Miranda Pedroso R, González Tapia M, Monzón Tamargo M de J, Pozo Pozo D. Uso del Heberprot-P 75 en paciente con Pie diabético Grado 3. Rev Ciencias Médicas Pinar del Río. 2019 [acceso 11/06/2021];23(2):351-5. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942019000200351&lng=es
Fernández Montequín JI, La O Hernández E, Suen Díaz J E. Stimul W(r) y Heberprot-P(r) unidos en el tratamiento de la úlcera del pie diabético. Rev Cubana Angiol Cir Vasc. 2021 [acceso 11/07/2021];22(1):e300. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1682-00372021000100012&lng=es
Sánchez González C, Rodríguez Rodríguez J, Galardi Martínez K, Matech Hernández L. (2020). Estándares reguladores de avanzada para medicamentos y productos biotecnológicos en Cuba. Rev Cubana Farmacia. 2020 [acceso 11/07/2021];53(2). Disponible en: http://www.revfarmacia.sld.cu/index.php/far/article/view/423